AAV Formulation Development

In the field of gene therapy, AAV formulation development has gained significant focus. AAV vectors are used as delivery vehicles or "vectors" to administer therapeutic genes into patient's cells. This therapeutic gene, once inside the cell, generates a functional protein to correct or counter the effects of the disease-causing genetic mutation, providing a basis for curing several genetic diseases.

The AAV's natural origin makes it an ideal vector for human gene therapy, attributed to its lack of pathogenicity and low immunogenicity. Many variants of AAV exist, each having unique properties that make them suitable for distinct applications, from ocular gene therapy to curing muscular dystrophy, hemophilia, and other genetic diseases.

However, despite these promising attributes, the AAV formulation development process is not without its challenges. Successful AAV formulation demands understanding factors such as administration routes and organ-specific distribution, stability, vector aggregation, manufacturing-related impurities, and vector-host interactions.
Source https://www.bocsci.com/aav-formulation-development.html ↗